Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

No absolutes

Daniel Hackam
CMAJ September 30, 2003 169 (7) 651-651-a;
Daniel Hackam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Anthony Kerrigan states that relative risk reduction does not take into account primary and secondary end points (which are expressed by absolute risk reduction) and that presenting absolute risk reductions would give practitioners more realistic estimates of the benefits of specific interventions. Although this viewpoint has been frequently expressed in letters to the editor and editorials, its premise is flawed.

Patients enrolled in clinical trials are frequently at lower risk of important adverse outcomes than the patients commonly encountered in actual practice, many of whom have risk-increasing comorbidities that tend to exclude them from such studies. Therefore, the absolute risk reduction reported in a pertinent clinical trial cannot readily be applied to such patients. The obvious solution is to calculate a new absolute risk reduction (and a new number needed to treat) based on the relative risk reduction reported in the clinical trial, as applied to the patient's estimated baseline, pretreatment risk.1 Fortunately, the relative risk reductions derived from cardiovascular trials tend to be relatively impervious to the baseline risk of the patient. Therefore, as implied by my summary2 of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),3 it is entirely appropriate for practitioners to apply the relative, not the absolute, risk reduction from such clinical trials to the patients they see.

Daniel Hackam Division of Clinical Pharmacology Department of Medicine University of Toronto Toronto, Ont.

References

  1. 1.↵
    Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the number needed to treat (NNT)? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002; 31: 72-6.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Hackman DG. Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy? CMAJ 2003;168(13):1689.
    OpenUrlFREE Full Text
  3. 3.↵
    ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361: 1149-58.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (7)
CMAJ
Vol. 169, Issue 7
30 Sep 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
No absolutes
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
No absolutes
Daniel Hackam
CMAJ Sep 2003, 169 (7) 651-651-a;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
No absolutes
Daniel Hackam
CMAJ Sep 2003, 169 (7) 651-651-a;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Coexisting failures do not diminish the stature of a giant
  • Dare we hope
  • Highlighting obesity as a risk factor for endometrial cancer
Show more Letters

Similar Articles

Collections

  • Topics
    • Stroke
    • Drugs: cardiovascular system
    • Cardiology: ischemic heart disease
    • Cardiology: hypertension

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire